Enhancement of placental stem cell potency using modulatory rna molecules
AssigneeAnthrogenesis Corporation
InventorsStewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.
Claims23
A method of treating an individual having or at risk of developing a disease, disorder or condition having an inflammatory component, comprising administering to the individual a therapeutically effective amount of enhanced placental stem cells,
- wherein said cells comprise or have been contacted with an effective amount of modulatory RNA molecules that
- (i) suppress an amount of soluble IL-23 protein produced by peripheral blood mononuclear cells (PBMCs) in the presence of said enhanced placental stem cells;
- (ii) increase cyclooxygenase II (Cox-2) activity in said enhanced placental stem cells;
- (iii) increase an amount of PGE2 produced by said enhanced placental stem cells;
- or
- (iv) reduce the level a pro-inflammatory cytokine produced by enhanced placental stem cells,
- compared to placental stem cells not contacted with said modulatory RNA molecules,
- wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said disease, disorder or condition.
A pharmaceutical composition for treating an individual having or at risk of developing a disease, disorder or condition having an inflammatory component, said pharmaceutical composition comprising a therapeutically effective amount of enhanced placental stem cells,
- wherein said cells comprise or have been contacted with an effective amount of modulatory RNA molecules that, when compared to placental stem cells not contacted with said modulatory RNA molecules
- (i) suppress an amount of soluble IL-23 protein produced by peripheral blood mononuclear cells (PBMCs) in the presence of said enhanced placental stem cells;
- (ii) increase Cox-2 activity in said enhanced placental stem cells;
- (iii) increase an amount of PGE2 produced by said enhanced placental stem cells;
- or
- (iv) reduce the level a pro-inflammatory cytokine produced by enhanced placental stein cells,
- wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said disease, disorder or condition.
A method of modifying placental stem cells comprising contacting the placental stem cells with an effective amount of modulatory RNA molecules, such that said placental stem cells, after having been contacted with said modulatory RNA molecules
- (i) suppress an amount of soluble IL-23 protein produced by peripheral blood mononuclear cells (PBMCs) in the presence of said placental stem cells;
- (ii) increase cyclooxygenase II (Cox-2) activity in said placental stem cells;
- (iii) increase an amount of PGE2 produced by said placental stem cells;
- or
- (iv) reduce the level a pro-inflammatory cytokine produced by said placental stem cells,
- as compared to an equivalent amount of placental stem cells not contacted with said modulatory RNA molecules.
A composition comprising enhanced placental stem cells, wherein said enhanced placental stem cells comprises one or more modulatory RNA molecules, and wherein said enhanced placental stem cells
- (i) suppress an amount of soluble IL-23 protein produced by peripheral blood mononuclear cells (PBMCs) in the presence of said enhanced placental stem cells;
- (ii) increase cyclooxygenase II (Cox-2) activity in said enhanced placental stem cells;
- (iii) increase an amount of PGE2 produced by said enhanced placental stem cells;
- or
- (iv) reduce the level a pro-inflammatory cytokine produced by enhanced placental stem cells,
- as compared to an equivalent amount of placental stem cells not contacted with said modulatory RNA molecules.
Dependencies are inferred from the claim text.